The chief objectives are to reduce the patient’s symptom duration and severity, prevent both acute and delayed complications, and forestall an overspill of the infection to others.
Last year saw remarkable advances, with seven products approved by the FDA, and currently 500 products are in the U.S. pipeline, with 10 to 20 new approvals expected in 2025.